Lannett receives aproval for generic Imitrex nasal spray for the treatmentof migranes... Good Luck!

Discussion in 'Avanir Pharmaceuticals' started by anonymous, Feb 22, 2016 at 3:52 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    You are going to need it with this noseblower crap. 10x the price and still have to blow this crap up your nose!! LOL. Good lord!
     

  2. anonymous

    anonymous Guest

    The Puffer concept made sense about 10 years ago.
    Chat with the Teva boys about how Zecuity is doing.
    I hope noone took a job with Avanir unless they were unemployed as this is a major dud.
     
  3. anonymous

    anonymous Guest

    Puff Puff

    Can i put Imitrex in my Vap Pen instead?
     
  4. anonymous

    anonymous Guest

    Our Puffer is way better than spray, just look at the data, people dont like nasal sprays anyway
     
  5. anonymous

    anonymous Guest

    Leaving USL to come to this shit hole was a big mistake
     
  6. anonymous

    anonymous Guest

    I must have missed that HTH data that the doctors want to see about how much better it is?
    Off Label perhaps? Thats the Avanir way!
     
  7. anonymous

    anonymous Guest

    Upsher management is so insecure they are now defending their debacle here? Go fix your own mess and leave the real companies alone!
     
  8. anonymous

    anonymous Guest


    Yeah, ok. Looks like Chris's skinny jeans are too tight again.

    USL can't do anything right. Shouldn't U be planning the next cheerleading , aka "we will get them next time guys" speech?
     
  9. anonymous

    anonymous Guest

    Dont you puff it up your nose? Do a lot of people prefer puffing vs spraying?
     
  10. anonymous

    anonymous Guest

    The person who signed the contract to bring the puffer technology here should be black balled from the industry period. Who in the world thought this delivery system would be a good idea!!?? This is a classic case of a terrible solution trying to create a problem in the market. This will fail miserably mark my words....
     
  11. anonymous

    anonymous Guest

    we are not a puffer or a spray we are a intra nasal delivery system there's nothing else like it. And the physicians actually seem to like it and the migraine market is so huge . The powder being delivered deep into the nasal cavity seems to be effective .
     
  12. anonymous

    anonymous Guest

    You realize that sumatriptan (Imitrex) nasal spray has been generic for years, right? Amateur hour.
     
  13. anonymous

    anonymous Guest

    And so do the drug abusers
    Get the cocaine exactly where they want it
     
  14. anonymous

    anonymous Guest

    Can you imagine having to walk into a doctors office with your nose blowing contraption when products like this are/will be availabile?!?!


    New Drug To Prevent Migraine May Start Working In Days, Teva (TEVA) Reveals

    iMINNEAPOLIS - A new drug to prevent migraine was associated with fewer headache hours for people with chronic migraine within three to seven days after the first injection, according to a study published in the June 8, 2016, online issue of Neurology®, the medical journal of the American Academy of Neurology. Chronic migraine is defined as headaches occurring at least 15 days per month. Study participants had migraine attacks for an average of 20 years prior to treatment.
    "Chronic migraine affects about 1 percent of all adults, yet less than 5 percent of those people receive a correct diagnosis and appropriate treatment," said study author Marcelo Bigal, MD, PhD, of Teva Pharmaceuticals in Frazer, Penn., which developed the new drug, called TEV-48125. "Most people who receive preventive medication for chronic migraine stop using them, and one reason for that is the drugs can take a long time to become effective. If these results can be confirmed with larger studies, this could be exciting for people with migraine."

    TEV-48125 is an antibody that blocks the calcitonin gene-related peptide that plays a role in migraine pain. The study involved 261 people who had migraine for an average of 18 years. They had an average of 162 hours of headaches a month and an average of 22 days with headache per month.

    Of the participants, 87 people received a monthly shot for three months with a low dose of the drug, 85 people received a high dose and 89 people received a placebo shot. The participants used an electronic diary to record their headaches. The phase 2b study was conducted to look for the results after three months, and the positive results were published. For this study, the researchers reanalyzed the results to look at the results on headache hours and days in the first days and weeks of the study.

    After one week, the average number of headache hours went down by 2.9 hours for people taking the placebo, 9.1 hours for people taking the low dose of TEV-48125 and 11.4 hours for those taking the high dose. The higher dose first showed a difference from the placebo after three days, with 3.1 fewer headache hours, compared to an additional 0.4 hours for the placebo. The lower dose showed a difference from the placebo after seven days, with 7.3 fewer headache hours, compared to 1.6 fewer hours for the placebo.

    For the number of days with moderate or severe headaches, both doses showed a difference from placebo after two weeks of treatment, with headaches reduced by 0.8 days for placebo, 1.3 days for the low dose and 1.5 days for the high dose.

    Bigal noted that study limitations include that the analyses for the early results were not defined before the study was conducted and that study participants were not asked whether the results in the first days of the study were large enough to be meaningful for them.
     
  15. anonymous

    anonymous Guest

    Teva and Antares Pharma Announce Launch of Generic Imitrex® in the United States
    JERUSALEM & EWING, N.J.--(BUSINESS WIRE)--Jun. 27, 2016-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) and Antares Pharma, Inc. (NASDAQ:ATRS) today announced the launch of the generic equivalent to Imitrex®1 (sumatriptan succinate) injection, 4 mg and 6 mg single-dose, prefilled syringe autoinjectors, in the U.S. Sumatriptan injection is used to treat acute migraine with or without aura, and acute cluster headaches in adults. Sumatriptan injection is self-administered subcutaneously into the back of arm or outer thigh.

    Approximately 36 million people in the U.S. suffer from migraine and its various characteristics. According to the American Migraine Study II, 85 percent of respondents experience throbbing pain, 80 percent experience sensitivity to light, 76 percent experience sensitivity to sound and 73 percent experience nausea.

    "We are pleased to add sumatriptan injection to our growing portfolio through our successful partnership with Antares,” stated Siggi Olafsson, President and CEO, Global Generic Medicines, Teva. “This achievement demonstrates our ability to leverage our leadership in the pharmaceutical industry, and our ongoing commitment to our patients, customers and the communities that we serve.”

    Teva remains committed to strengthening its presence in the treatment of migraine and its generic injectable business globally. Teva continues investment in new, and higher-value generic injectable products. With approximately 370 generic medicines available, Teva has the largest portfolio of FDA-approved generic products and continues to bring new products to market for the patients who need them.

    “We are delighted to offer this product to patients in the United States through our partner, Teva,” said Robert F. Apple, President and CEO, Antares Pharma. “With the approval and launch of sumatriptan injection, we remain optimistic on progress of our other combination product development programs with Teva, which are currently under FDA review.”

    Sumatriptan injection had annual sales of approximately $183 million in the United States, according to IMS data as of March 2016.
     
  16. anonymous

    anonymous Guest

    This place is in serious trouble....